研究报告 Research Report 6 May 2025 双箭股份 Zhejiang Double Arrow Rubber (002381 CH) 扣非后净利润同比下降 37.70%，在建项目进展顺利 Recurring Net Profit -37.70% YOY, Projects under Construction are Progressing Well [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 Rmb6.39 目标价 Rmb7.84 HTI ESG 4.0-4.0-4.5 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 Rmb2.06bn / US$0.28bn 日交易额 (3 个月均值) US$6.72mn 发行股票数目 322.03mn 自由流通股 (%) - 1 年股价最高最低值 Rmb8.05-Rmb5.95 注：现价 Rmb6.39 为 2025 ...

研究报告 Research Report 5 May 2025 三美股份 Zhejiang Sanmei Chemical Industry (603379 CH) 业绩保持增长，看好三代制冷剂景气周期 公司业绩大幅增长。公司 2024 年营业收入 40.4 亿元，同比增长 21.17%；归属于母公司所有者的净利润 7.79 亿元，同比增长 178.4%，其中 2024Q4 营业收入 10.00 亿元，同比+37.98%，环比 +0.10%，归母净利润 2.18 亿元，同比+423.08%，环比+22.85%。 2025 年一季度营业收入 12.12 亿元，同比增长 26.42%，环比 +21.17%；归属于母公司所有者的净利润 4.01 亿元，同比增长 159.59%，环比+84.01%。 制冷剂价格保持涨势，公司盈利能力显著提高。2024 年公司制 冷剂产量/销量 16.26/12.34 万吨，分别同比+3.88%/+1.62%，制 冷剂价格 26055.9 元/吨，同比+28.17%，其中第四季度制冷剂价 格同比+48.49%，环比+6.09%。2025 年第一季度，公司制冷剂产 量/销量 4.09 万 ...

Investment Rating - The report maintains an "Outperform" rating for the company [1][2][16]. Core Views - The company experienced a revenue decline of 17.9% year-on-year in Q1 2025 due to a high base effect, with revenue reported at RMB 660 million. However, there was a slight quarter-on-quarter growth of 1.5% compared to Q4 2024 [3][11]. - The gross margin remained stable at 93.9%, while operating expenses increased due to higher sales, administrative, and R&D expense ratios [12]. - Non-recurring gains offset the revenue decline, leading to a net profit of RMB 440 million, down 15.9% year-on-year, with a net profit margin of 66.9% [13]. - The company is planning to acquire 85% of South Korean company REGEN, which is expected to significantly contribute to revenue and profits starting in 2026 [14][16]. - Revenue and net profit forecasts for 2025 and 2026 are projected at RMB 3.30 billion and RMB 3.60 billion, and RMB 2.02 billion and RMB 2.18 billion respectively, indicating year-on-year growth of 9.2% and 9.1% for revenue, and 3.1% and 7.7% for net profit [15][16]. Financial Summary - For 2025, the company is expected to achieve revenue of RMB 3.30 billion and net profit of RMB 2.02 billion, with respective growth rates of 9.2% and 3.1% [15]. - The projected diluted EPS for 2025 is RMB 6.67, with a P/E ratio of 26 [5][9]. - The company maintains a strong gross profit margin of 94.6% for 2025, with a projected return on equity (ROE) of 20.6% [5][9].

[Table_Title] 研究报告 Research Report 5 May 2025 康鹏科技 Shanghai Chemspec (688602 CH) 康鹏科技 (688602 CH): 归母净利润同比下降 143.95%，ETO 产线扩产 2027 年落地 Shanghai Chemspec: NPAtS Down 143.95% YOY, ETO Production Line Expansion to Be Implemented in 2027 孙小涵 Xiaohan Sun 2024 年归母净利润-0.50 亿元，同比下降 143.95%。公司 2024 年实现营业收入 6.75 亿元，同比下降 31.11%，实 现归母净利润-0.50 亿元同比下降 143.95%。其中 2024 年四季度实现营业收入 1.51 亿元，同比下降 18.32%，环 比下降 17.46%，实现归母净利润-0.32 亿元，同比下降 1881.03%，环比下降 23.64%。2024 年地缘政治影响日益 加深，国际贸易面临的外部不确定性持续上升，整体市场表现疲弱。在此背景下，公司新材料产品产销量分别 为 3786 ...

Investment Rating - The report maintains an "Outperform" rating for Chart Industries, expecting a relative return exceeding 10% over the next 12-18 months [12]. Core Insights - Chart Industries reported slightly better-than-expected earnings for Q1 2025, driven by strong performance in specialty products and a solid backlog of orders [1][2]. - The company reaffirmed its revenue guidance for FY 2025, projecting revenue between $4.65 billion and $4.85 billion, with adjusted EBITDA expected to be between $1.175 billion and $1.225 billion [3]. - The backlog of orders reached a record high of $5.14 billion, indicating strong demand and future revenue potential [2]. Financial Performance Summary - Adjusted net income for Q1 2025 was $84 million, slightly above the consensus estimate of $79 million, while revenue was $1.002 billion, close to the expected $1.01 billion [2][5]. - The adjusted EBITDA for the quarter was $231 million, exceeding the consensus estimate of $228 million, with a gross margin of 33.9% [2][5]. - Free cash flow for the quarter was reported at $80 million, compared to $261 million in Q4 2024 [2]. Guidance and Strategic Outlook - The company reiterated its mid-term guidance, expecting organic revenue growth in the mid-teens and maintaining a gross margin in the mid-30% range [3]. - Chart Industries anticipates that the impact of tariffs will be limited and can be offset by cost reductions and strategic pricing actions [3].

[Table_Title] 研究报告 Research Report 2 May 2025 克丽维能源 (CWEN US) 强劲利润率表现；重申 CAFD 指引；产能建设如期推进 Scott Darling Catherine Li scott.darling@htisec.com catherine.dy.li@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (本报告为 2025 年 5 月 1 日发布的英文报告的翻译版，以原稿为准) 要闻回顾以及最新动态 我们预计 Clearway Energy2025 年第一季度业绩将被市场反应为积极。公司录得的经调净收入超一致预期，录得经调 息税折摊前利润 2.52 亿美元，超一致预期。公司重申 2025 财年 4 亿-4.4 亿美元的可分配现金（CAFD）指引，并维持 2027 年后每股 CAFD 增长 5%-8%+的长期目标。 项目的商业运行（COD）产能建设按计划推进，2025 财年 1.1 吉瓦及 2026-2027 财年 2.3 吉瓦的产能交付指引维持不变。 | 损益表（百万 | 2 ...

英国石油公司【英国石油公司【表标题】 研究报告 2025 年 4 月 29 日 英国石油公司（BP US） 天然气和低碳业务亏损；资产剥离增加 Scott Darling Catherine Li Scott.darling@htisec.com Catherine.dy.li@htisec.com [Table_summary] （本报告为 2025 年 4 月 29 日发布的英文报告的翻译版,以原版为准。） 最新动态/新闻 我们预计，市场对英国石油公司（未被 HTI 覆盖）2025 年第一季度业绩反应略微负面，公司报告经调净收入为 13.81 亿美元，低于由低于预期的天然气和低碳部门驱动的一致预期。股息为 8.00 美分/股，同比增长 10%（2024 年第一季 度为 7.27 美分/股），远高于公司每年至少提供 4%股息增长的计划。股票回购为 7.5 亿美元，符合 2025 年第一季度 7.5 亿美元至 10 亿美元的先前指引。公司还重申了 2025 财年资本支出指引 150 亿美元（26/27 财年 130-150 亿美 元）和 2025 年下半年剥离至 30-40 亿美元（vs 30 亿美元）。公司 ...

Investment Rating - The report maintains an "Outperform" rating for the company [1]. Core Views - The company continues to experience rapid growth, with a significant increase in electrophysiology procedures and potential growth in peripheral products due to centralized procurement [1][5]. - The target price has been adjusted to 504.27, reflecting a 40% upside from the current price of 433.06 [1][5]. Financial Summary - For 2024, the company is projected to achieve revenue of 2,066 million, representing a growth of 25.2%, and a net profit of 673 million, reflecting a growth of 26.1% [3][5]. - The first quarter of 2025 is expected to show revenue of 5.64 billion, a year-on-year increase of 23.93%, and a net profit of 1.83 billion, up 30.69% [5]. - The earnings per share (EPS) estimates have been adjusted to 9.34 for 2025 and 15.89 for 2027 [5]. Operational Highlights - The company has seen a 50% increase in three-dimensional electrophysiology procedures, with over 15,000 procedures completed in 2024 [5]. - The company’s electrophysiology revenue is expected to reach 4.4 billion, a growth of 19.73% [5]. - The company has successfully launched key products in the electrophysiology market, including AForcePlus catheters and a cardiac pulsed field ablation device [5]. Market Position - The company has expanded its market presence, with over 1,360 hospitals now using its electrophysiology products, and a significant increase in the number of hospitals adopting its coronary and peripheral products [5]. - International revenue is projected to grow by 19.75%, with a notable 45.88% increase in self-branded products in key markets [5].

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 68.77, representing a potential upside of 9% from the current price of RMB 55.17 [1][8]. Core Insights - The company's performance in Q1 2025 shows stable growth, with revenue reaching RMB 5.79 billion, up 7.59% year-on-year, and net profit attributable to shareholders at RMB 497 million, up 5.82% year-on-year [1][8]. - External sales growth is expected to outpace internal sales, driven by high demand and national subsidies, contributing to a positive outlook for 2025 [1][8]. - The gross profit margin (GPM) decreased by 0.51 percentage points to 23.91% in Q1 2025, while overall profitability remains stable despite increased competition in the domestic market [1][8]. Financial Summary - Revenue projections for the company are as follows: - 2023A: RMB 21,304 million - 2024A: RMB 22,427 million - 2025E: RMB 23,821 million - 2026E: RMB 25,073 million - 2027E: RMB 26,392 million - The year-on-year growth rates are 5.6%, 5.3%, 6.2%, 5.3%, and 5.3% respectively [3]. - Net profit attributable to shareholders is projected to be: - 2023A: RMB 2,180 million - 2024A: RMB 2,244 million - 2025E: RMB 2,397 million - 2026E: RMB 2,557 million - 2027E: RMB 2,708 million - The year-on-year growth rates are 5.4%, 3.0%, 6.8%, 6.7%, and 5.9% respectively [3]. - Earnings per share (EPS) estimates are: - 2025E: RMB 2.99 - 2026E: RMB 3.19 - 2027E: RMB 3.38 [3][8]. Company Outlook - For 2025, the company anticipates selling RMB 7.37 billion worth of goods to SEB, reflecting a 5% year-on-year increase, supported by trade-in programs and market share growth [1][8].

Investment Rating - The report assigns an "Outperform" rating to the company with a target price of RMB 28.39 based on a 17x PE for 2025 [4][12]. Core Views - The company is expected to achieve stable revenue growth, with 2024 revenue projected at RMB 5.89 billion (+10.12%) and net profit attributable to shareholders at RMB 0.78 billion (+27.61%) [4][12]. - The veterinary medicine segment is anticipated to contribute significantly to revenue growth, with a projected revenue of RMB 2.02 billion in 2024 (+10.0%) [4][13]. - The company is enhancing its global operations, with products sold in 115 countries and regions, establishing a strong position in the global pharmaceutical manufacturing industry [4][14]. Financial Summary - Revenue and net profit forecasts for 2024 and 2025 are as follows: - 2024 Revenue: RMB 5.89 billion (+10.12%) - 2024 Net Profit: RMB 0.78 billion (+27.61%) - 2025 Revenue: RMB 6.60 billion (+12.1%) - 2025 Net Profit: RMB 0.93 billion (+19.5%) [3][4][12]. - Earnings per share (EPS) are projected to be RMB 1.67 in 2025, RMB 2.01 in 2026, and RMB 2.36 in 2027 [4][12]. Business Segments - The pharmaceutical raw materials segment is benefiting from high demand for macrolide antibiotics, with a projected revenue of RMB 2.48 billion in 2024 (+11.7%) and a gross profit margin of 28.4% [4][13]. - The veterinary medicine business is expanding, with significant sales growth expected due to improved market conditions and product certifications [4][13][14]. Global Operations - The company is focusing on globalization and integration, with over 70 active pharmaceutical ingredients and intermediates expected to be produced and sold in 2024 [4][14]. - The company has established sales channels in multiple countries, enhancing its global reach and operational capabilities [4][14].